Wnt signalling in gynaecological cancers: A future target for personalised medicine?

Gynecologic Oncology

Volumn 140, Issue 2, 2016, Pages 345-351

  Ford, C E ^a   Henry, C ^a   Llamosas, E ^a   Djordjevic, A ^a   Hacker, N ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cervical cancer; Ovarian cancer; ROR1; ROR2; Uterine cancer; Wnt

Indexed keywords

BETA CATENIN; PROTEIN TYROSINE KINASE; WNT PROTEIN; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CELL MIGRATION; CELL POLARITY; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; NONHUMAN; OVARY CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERUS CANCER; WNT SIGNALING PATHWAY; ANIMAL; GENITAL NEOPLASMS, FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; BIOMARKERS, TUMOR; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; WNT SIGNALING PATHWAY;

EID: 84945963753     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.09.085     Document Type: Review

References (70)

1. J. Ferlay, and et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur. J. Cancer 49 6 2013 1374 1403
2. T.C.G. Atlas Integrated genomic analyses of ovarian carcinoma Nature 474 7353 2011 609 615
3. Cancer Genome Atlas Research Netwrok, and et al. Integrated genomic characterization of endometrial carcinoma Nature 497 7447 2013 67 73
4. R.G. Verhaak, and et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma J. Clin. Invest. 123 1 2013 517 525
5. E.M. Berns, and D.D. Bowtell The changing view of high-grade serous ovarian cancer Cancer Res. 72 11 2012 2701 2704
6. R.W. Tothill, and et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin. Cancer Res. 14 16 2008 5198 5208
7. A.M. Patch, and et al. Whole-genome characterization of chemoresistant ovarian cancer Nature 521 7553 2015 489 494
8. B. Madan, and D.M. Virshup Targeting Wnts at the source - new mechanisms, new Biomarkers New Drugs Mol. Cancer. Ther. 14 5 2015 1087 1094
9. R. van Amerongen, A. Mikels, and R. Nusse Alternative wnt signaling is initiated by distinct receptors Sci Signal 1 35 2008 re9
10. L. Grumolato, and et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors Genes Dev. 24 22 2010 2517 2530
11. J. Anastas, and R. Moon WNT signalling pathways as therapeutic targets in cancer Nat. Rev. Cancer 13 2013 11 26
12. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat. Rev. Cancer 10 11 2010 803 808
13. F.R. Nezhat, and et al. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention Am. J. Obstet. Gynecol. 2015
14. S. Yoshioka, and et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/beta-catenin pathway Molecular Cancer Research: MCR 10 3 2012 469 482
15. M.L. King, and et al. WNT7A/[beta]-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer Oncogene 34 26 2015 3452 3462
16. Jacob, F.; et al.; Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients. PLoS One, 2012. 7(2): p. e31885.
17. C.E. Ford, and et al. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells PLoS One 2013 8(1)
18. H.Y. Su, and et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway Int. J. Cancer 2009
19. A. You, and et al. Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer J. Cancer Res. Clin. Oncol. 137 4 2011 621 627
20. J. Zhu, and et al. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma Carcinogenesis 33 12 2012 2334 2343
21. S. Wang, and S. Zhang Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion Clin. Exp. Metastasis 28 6 2011 581 591
22. K. Tomizuka, and et al. R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling Hum. Mol. Genet. 17 9 2008 1278 1291
23. P.H. van der Horst, and et al. Interaction between sex hormones and WNT/beta-catenin signal transduction in endometrial physiology and disease Mol. Cell. Endocrinol. 358 2 2012 176 184
24. L. Bodnar, and et al. Wnt/beta-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer J. Ovarian Res. 7 2014 16
25. K. Rask, and et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta Br. J. Cancer 89 7 2003 1298 1304
26. J. Wang, and et al. CD44v6 promotes beta-catenin and TGF-beta expression, inducing aggression in ovarian cancer cells Mol. Med. Rep. 11 5 2015 3505 3510
27. H. Zhao, and et al. Interference with the expression of beta-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model DNA Cell Biol. 34 1 2015 55 62
28. W. Kildal, and et al. Beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients Eur. J. Cancer 41 8 2005 1127 1134
29. C. Gamallo, and et al. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome Am. J. Pathol. 155 2 1999 527 536
30. Minami, Y.; et al.; Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev. Dyn.; 2010. 239(1): p. 1-15.
31. L. Badiglian Filho, and et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer Oncol. Rep. 21 2 2009 313 320
32. C.E. Ford, and et al. The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer Gynecol. Oncol. 134 2 2014 338 345
33. C. Peng, and et al. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer Int. J. Gynecol. Cancer 21 2 2011 280 288
34. S. Chen, and et al. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma Int. J. Mol. Sci. 14 12 2013 24187 24199
35. H. Qi, and et al. Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer Oncol. Rep. 32 2 2014 771 779
36. B.G. Bitler, and et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence Cancer Res. 71 19 2011 6184 6194
37. F.G. Giancotti Mechanisms governing metastatic dormancy and reactivation Cell 155 4 2013 750 764
38. F. Jannesari-Ladani, G. Hossein, and N. Izadi-Mood Differential Wnt11 expression related to Wnt5a in high- and low-grade serous ovarian cancer: implications for migration, adhesion and survival Asian Pac. J. Cancer Prev. 15 3 2014 1489 1495
39. S. Zhang, and et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy Proc. Natl. Acad. Sci. U. S. A. 111 48 2014 17266 17271
40. H. Zhang, and et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer Sci. Rep. 4 2014 5811
41. Y. Liu, and et al. Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer Int. J. Gynecol. Cancer 23 2 2013 304 311
42. K.S. Carmon, and D.S. Loose Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells Mol. Cancer Res. 6 6 2008 1017 1028
43. P. Menezes Mde, and et al. Canonical and noncanonical Wnt pathways: a comparison between endometrial cancer type I and atrophic endometrium in Brazil Sao Paulo Med. J. 129 5 2011 320 324
44. C. Peng, and et al. Expression and prognostic significance of wnt7a in human endometrial carcinoma Obstet. Gynecol. Int. 2012 2012 134962
45. T. Dellinger, and et al. Dkk3 Wnt inhibitor expression in endometrial cancer predicts pelvic lymph node status, and correlates with clinicopathologic factors Gynecol. Oncol. 127 1 Suppl 2012 S20
46. T.H. Dellinger, and et al. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer Gynecol. Oncol. 126 2 2012 259 267
47. R. Eskander, and et al. Expression patterns of the Wnt pathway inhibitor dickKOPF-3 (Dkk3) and secreted frizzled-related proteins (sFRP) 1 and 4 in endometrial endometrioid adenocarcinoma: a gynecologic oncology group study Gynecol. Oncol. 127 1 Suppl 2012 S5
48. Yi, N.; et al.; RNA interference-mediated targeting of DKK1 gene expression in Ishikawa endometrial carcinoma cells causes increased tumor cell invasion and migration. Oncol. Lett.; 2013. 6(3): p. 756-762.
49. H. Chen, Y. Wang, and F. Xue Expression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/beta-catenin pathway Oncol. Rep. 29 2 2013 507 514
50. Y. Liu, and et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma J. Natl. Cancer Inst. 2014 106(9)
51. M.K. McConechy, and et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles Mod. Pathol. 27 1 2014 128 134
52. P.W. Schlosshauer, L.H. Ellenson, and R.A. Soslow Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype Mod. Pathol. 15 10 2002 1032 1037
53. A.N. Scholten, and et al. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma J. Pathol. 201 3 2003 460 465
54. J.M. Pijnenborg, and et al. APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma Int. J. Gynecol. Cancer 14 5 2004 947 956
55. J.H. Shepherd Cervical cancer Best Practice & Research Clinical Obstetrics & Gynaecology 26 3 2012 293 309
56. M.T. Chung, and et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway Gynecol. Oncol. 112 3 2009 646 653
57. Y.-W. Lin, and et al. Methylation analysis of SFRP genes family in cervical adenocarcinoma J. Cancer Res. Clin. Oncol. 135 12 2009 1665 1674
58. J. Lee, Y.S. Yoon, and J.H. Chung Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines Gynecol. Oncol. 109 2 2008 270 274
59. G. Bulut, and et al. Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice PLoS One 6 11 2011 e27243
60. S.P. García-Zepeda, and et al. Resveratrol induces cell death in cervical cancer cells through apoptosis and autophagy Eur. J. Cancer Prev. 22 6 2013 577 584
61. H.J. Chen, and et al. The beta-catenin/TCF complex as a novel target of resveratrol in the Wnt/beta-catenin signaling pathway Biochem. Pharmacol. 84 9 2012 1143 1153
62. H. Wei, and et al. Clinical significance of Wnt-11 and squamous cell carcinoma antigen expression in cervical cancer Med. Oncol. 31 5 2014 933
63. B. Sun, and et al. Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer Int. J. Clin. Exp. Pathol. 8 1 2015 856 861
64. M. Kahn Can we safely target the WNT pathway? Nat. Rev. Drug Discov. 13 7 2014 513 532
65. R.C. Arend, and et al. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer Gynecol. Oncol. 134 1 2014 112 120
66. W. Lu, and et al. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway PLoS One 6 12 2011 e29290
67. T. Osada, and et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations Cancer Res. 71 12 2011 4172 4182
68. M. Chen, and et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling Biochemistry 48 43 2009 10267 10274
69. Hojjat-Farsangi, M.; et al.; The receptor tyrosine kinase ROR1 - an oncofetal antigen for targeted cancer therapy. Semin. Cancer Biol.; 2014. 29(0): p. 21-31.
70. Nusse, R.; D.E.R.J.M. Van, and B. Edris, Analysis and targeting of ror2 in cancer. 2013, Google Patents.